网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
靶向逆转NM23对非小细胞肺癌放疗敏感性的影响及其可能机制
作者:夏露花1 2  崇乐3  王新华2  董占飞2  万晶晶2  秦永德1 
单位:1. 新疆医科大学第一附属医院 核医学科, 新疆 乌鲁木齐 830054;
2. 新疆医科大学附属肿瘤医院 核医学科, 新疆 乌鲁木齐 830011;
3. 新疆医科大学附属肿瘤医院 超声科, 新疆 乌鲁木齐 830011
关键词:非小细胞肺癌 核苷二磷酸激酶1 靶向逆转 放疗敏感性 
分类号:R734.2
出版年·卷·期(页码):2019·38·第十期(1210-1214)
摘要:

目的:分析靶向逆转核苷二磷酸激酶1(NM23)对非小细胞肺癌(NSCLC)放疗敏感性的影响及其可能机制。方法:将NSCLC细胞株A549分为对照组和实验组两组,对照组仅予照射处理,实验组在过表达NM23重组质粒转染A549后再予照射处理;用克隆形成实验检测各组细胞集落形成;用实时荧光PCR检测各组NM23 mRNA表达,蛋白质印迹法检测各组磷脂酰肌醇3-激酶(PI3K)和蛋白激酶B(AKT)蛋白表达。结果:与对照组比较,实验组平均致死剂量(MLD)值和2 Gy照射后的细胞存活分数(SF2)值均明显降低(P<0.05),各剂量存活率明显降低,各剂量NM23 mRNA表达水平明显增高,各剂量PI3K和AKT蛋白相对表达水平明显降低(P<0.05),对照组和实验组分别在4 Gy和2 Gy时以上变化最明显。结论:靶向逆转NM23可增强NSCLC放疗敏感性,与PI3K/AKT/mTOR信号通路相关。

Objective:To analyze the effect of targeted reversal of nucleoside diphosphate kinase 1(NM23) on radiosensitivity of non-small cell lung cancer(NSCLC) and to explore its possible mechanism.Methods:NSCLC A549 cells were divided into control group and experimental group. In the control group A549 cells were given irradiation treatment. In the experimental group, A549 cells were irradiated after the over-expressed NM23 recombinant plasmid was transfected into them. The colony formation was detected by colony formation assay. The expression of NM23 mRNA was detected by real-time fluorescent PCR. The expression of phosphatidylinositol 3-kinase(PI3K) and protein kinase B(AKT) was detected by Western blotting.Results:Compared with the control group, the MLD value and SF2 value of the experimental group were significantly decreased(P<0.05). Compared with the control group, the survival rate of each dose in the experimental group was significantly decreased, and the expression level of NM23 mRNA was significantly increased at each dose. The relative expression levels of PI3K and AKT protein were significantly decreased at each dose(P<0.05). The above changes were most obvious in the experimental group at 4 Gy and 2 Gy, respectively. Conclusion:Targeted reversal of NM23 can enhance the radiosensitivity of non-small cell lung cancer,which is associated with PI3K/AKT/mTOR signaling pathway.

参考文献:

[1] SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics,2016[J].CA Cancer J Clin,2016,66(1):7-30.
[2] HIRSCH F R,SCAGLIOTTI G V,MULSHINE J L,et al.Lung cancer:current therapies and new targeted treatments[J].Lancet,2017,389(10066):299-311.
[3] RASOOL R U,NAYAK D,CHAKRABORTY S,et al.Differential regulation of NM23-H1 under hypoxic and serum starvation conditions in metastatic cancer cells and its implication in EMT[J].Eur J Cell Biol,2017,96(2):164-171.
[4] ZHENG Z,TIAN R,WANG P.Roles of KAI1 and nm23 in lymph angiogenesis and lymph metastasis of laryngeal squamous cell carcinoma[J].World J Surg Oncol,2017,15(1):211-216.
[5] 张炜,郭万华,李爱梅,等.中晚期非小细胞肺癌骨转移与EGFR基因突变相关分析[J].东南大学学报(医学版),2018,37(4):711-715.
[6] POTEL C M,FASCI D,HECK A J R.Mix and match of the tumormet astasis suppressor Nm23 protein isoforms in vitro and in vivo[J].FEBS J,2018,285(15):2856-2868.
[7] NIE M,QIN Y,ZHU J,et al.Correlation between ultrasonic features and expression levels of C-erbB-2,VEGF and nm23 in breast cancer[J].Oncol Lett,2018,16(2):1701-1707.
[8] OZTURK E,AKSOY S A,UGRAS N,et al.Coexistence of MACC1 and NM23-H1 dysregulation and tumor budding promise early prognostic evidence for recurrence risk of early-stage-colon cancer[J].APMIS,2018,126(2):99-108.
[9] 申潞艳,康晓征,孙宇,等.非小细胞肺癌切除组织中常用免疫组织化学指标尚不能预测远期生存[J].中国肺癌杂志,2016,19(3):147-152.
[10] 刘珍,苏小岩,胡艳,等.调强放疗单用与联合化疗对不同亚组鼻咽癌远期疗效的影响[J].热带医学杂志,2016,16(5):654-657.
[11] O'DONNELL J S,MASSI D,TENG M W L,et al.PI3K-AKT-mTOR inhibition in cancer immunotherapy,redux[J].Semin Cancer Biol,2018,48:91-103.
[12] GUERRERO-ZOTANO A,MAYER I A,ARTEAGA C L.PI3K/AKT/mTOR:role in breast cancer progression,drug resistance,and treatment[J].Cancer Metastasis Rev,2016,35(4):515-524.
[13] 王峰,李梅,朱建伟,等.miRNA-221在行完全切除术非小细胞肺癌中的表达及患者生存分析[J].东南大学学报(医学版),2016,35(3):332-336.
[14] 周霖,薛兴阳.Ⅰ期非小细胞肺癌病灶中nm23的表达及淋巴结微转移研究[J].中国肿瘤外科杂志,2016,8(4):254-256,259.
[15] 唐泽飞,李春鸣.nm23重组质粒与肿瘤关系研究进展[J].中华实用诊断与治疗杂志,2016,30(1):12-14.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 295498 位访问者


 ©《现代医学》编辑部
联系电话:025-83272481;83272479
电子邮件: xdyx@pub.seu.edu.cn

苏ICP备09058541